DKFZ

oncology screening, AI CRISPR-data analysis; glioblastoma resistance.

Country: Germany

Coverage

	CN	EU	US
genome-engineering	✓	✓	✓
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Affiliation	Helmholtz Association of German Research Centers	dkfz.de
Research focus	oncology, glioblastoma resistance, AI in oncology, cancer neuroscience, tumor plasticity, brain tumor stem cells, and computational genomics	dkfz.de
Facility	Division of Molecular Neurogenetics, Division of AI in Oncology, Experimental Neurooncology group, Clinical Cooperation Unit Neurooncology, and Clinical Cooperation Unit Neuropathology	dkfz.de · nature.com
Grant	Carl-Zeiss-Stiftung (AI-Care project, MEDAL project), DFG (SFB 1389 UNITE Glioblastoma), BMBF, German Cancer Aid, Hertie Foundation, and Novo Nordisk Foundation	dkfz.de · nature.com · unite-glioblastoma.de
Publications	Numerous publications in journals including Nature, Nature Cancer, Cell Stem Cell, Neuron, and NPJ Precision Oncology	dkfz.de · nature.com
Principal staff	Haikun Liu, Moritz Gerstung, Lena Maier-Hein, Titus Brinker, Benedikt Brors, Annette Kopp-Schneider, Oliver Stegle, Martin Lablans, Karl-Friedrich Kowalewski, Klaus Maier-Hein, Angela Goncalves, Thomas Höfer, Stefanie Speidel, Daniel Hübschmann, Moritz Mall, and Brian Clarke	dkfz.de
Headcount	Approximately 250 researchers in Digital Oncology; over 3,000 employees total at DKFZ	dkfz.de

Independent sources: nature.com · unite-glioblastoma.de

Technologies

Name	Cluster	Risk
CRISPR screening as a service	genome-engineering	Low	→
Radiopharmaceuticals & theranostics	therapeutics-platforms	High	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.